Reply to Mercuro et al
Clin Infect Dis
.
2018 Sep 28;67(8):1307-1308.
doi: 10.1093/cid/ciy275.
Authors
Sarah Kabbani
1
,
Adam L Hersh
2
,
Daniel J Shapiro
3
,
Katherine E Fleming-Dutra
1
,
Andrew T Pavia
2
,
Lauri A Hicks
1
Affiliations
1
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
2
Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City.
3
Boston Combined Residency Program in Pediatrics, Boston Medical Center and Boston Children's Hospital, Massachusetts.
PMID:
29659745
PMCID:
PMC6160600
DOI:
10.1093/cid/ciy275
No abstract available
Publication types
Letter
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Comment
MeSH terms
Ambulatory Care*
Fluoroquinolones*
Humans
United States
Substances
Fluoroquinolones
Grants and funding
K08 HS023320/HS/AHRQ HHS/United States
R21 HD090955/HD/NICHD NIH HHS/United States
R01 AI125642/AI/NIAID NIH HHS/United States